Pfizer, Rib-X (Melinta), CURE
Dr. Froshauer is the President and CEO of CURE. She is an experienced scientist, mentor, entrepreneur, and investor with skill at connecting academic expertise and technology with the commercial sector. Prior to joining CURE, she was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role, Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs, and contribute to economic development. Until 2010, Susan served as President and CEO of Rib-X Pharmaceuticals, which she co-founded in New Haven in 2000. Under her leadership, Rib-X raised more than $160 million in private equity, bridge financing, and government grants and built a robust pipeline of antibiotics to treat serious hospital infections. Prior to Rib-X, Susan served as a member of Pfizer’s Strategic Alliance Group where she was key to the creation of a $200 million investment portfolio that transformed the Pfizer global research and development strategy, helping the company identify new resources for drug discovery.
Susan received a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a B. A. from Connecticut College. She performed post-doctoral research at Yale Medical School in the Department of Cell Biology as a Jane Coffin Child’s Fellow.